SenzaGen AB Asset Resilience Ratio

Latest as of September 2025: 29.75%

SenzaGen AB asset resilience ratio. SenzaGen AB (SENZA) has an Asset Resilience Ratio of 29.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of SenzaGen AB to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr29.27 Million
≈ $3.15 Million USD Cash + Short-term Investments

Total Assets

Skr98.37 Million
≈ $10.59 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of SenzaGen AB (2016–2024)

Asset resilience ratio of SenzaGen AB from 2016 to 2024. This chart shows how SenzaGen AB's Asset Resilience Ratio has changed over time. Read SenzaGen AB (SENZA) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down SenzaGen AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SenzaGen AB (SENZA) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr29.27 Million 29.75%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr29.27 Million 29.75%

Asset Resilience Insights

  • Very High Liquidity: SenzaGen AB maintains exceptional liquid asset reserves at 29.75% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

SenzaGen AB Industry Peers by Asset Resilience Ratio

Compare SenzaGen AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
Diagnostics & Research 15.15%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

SenzaGen AB Asset Resilience Ratio by Year (2016–2024)

SenzaGen AB asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for SenzaGen AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 35.39% Skr39.61 Million
≈ $4.26 Million
Skr111.91 Million
≈ $12.04 Million
+17.26pp
2023-12-31 18.14% Skr17.62 Million
≈ $1.90 Million
Skr97.18 Million
≈ $10.46 Million
-15.19pp
2022-12-31 33.33% Skr39.98 Million
≈ $4.30 Million
Skr119.95 Million
≈ $12.91 Million
-18.36pp
2021-12-31 51.69% Skr69.16 Million
≈ $7.44 Million
Skr133.81 Million
≈ $14.40 Million
-28.40pp
2020-12-31 80.09% Skr89.34 Million
≈ $9.61 Million
Skr111.55 Million
≈ $12.00 Million
-4.17pp
2019-12-31 84.27% Skr120.47 Million
≈ $12.96 Million
Skr142.96 Million
≈ $15.38 Million
+21.87pp
2018-12-31 62.39% Skr56.45 Million
≈ $6.07 Million
Skr90.47 Million
≈ $9.74 Million
-13.51pp
2017-12-31 75.90% Skr82.48 Million
≈ $8.88 Million
Skr108.67 Million
≈ $11.70 Million
+11.25pp
2016-12-31 64.65% Skr22.58 Million
≈ $2.43 Million
Skr34.92 Million
≈ $3.76 Million
--
pp = percentage points

About SenzaGen AB

ST:SENZA Sweden Diagnostics & Research
Market Cap
$15.69 Million
Skr145.75 Million SEK
Market Cap Rank
#25692 Global
#522 in Sweden
Share Price
Skr4.94
Change (1 day)
-1.98%
52-Week Range
Skr4.35 - Skr6.60
All Time High
Skr71.15
About

SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more